Senate Biosimilars Bill May Create Exclusivity For Pediatrics And Extra Indications, PhRMA Says

Sponsors are committed to firm 12 years of exclusivity, but evergreening remains an obstacle to reintroduction.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet